S&P 500   4,240.70 (+0.27%)
DOW   33,005.82 (+0.01%)
QQQ   357.48 (+0.72%)
AAPL   172.36 (-0.02%)
MSFT   317.00 (+1.15%)
META   302.04 (+0.37%)
GOOGL   133.92 (+1.13%)
AMZN   126.72 (+1.60%)
TSLA   252.46 (+2.41%)
NVDA   439.51 (+1.00%)
NIO   8.53 (-0.93%)
BABA   84.06 (-0.57%)
AMD   100.73 (+0.65%)
T   14.60 (-1.22%)
F   12.03 (-0.33%)
MU   67.82 (-0.01%)
CGC   0.68 (-1.19%)
GE   108.26 (+0.46%)
DIS   79.50 (-0.05%)
AMC   7.96 (+1.40%)
PFE   33.89 (-0.03%)
PYPL   58.03 (+1.27%)
NFLX   378.86 (+0.56%)
S&P 500   4,240.70 (+0.27%)
DOW   33,005.82 (+0.01%)
QQQ   357.48 (+0.72%)
AAPL   172.36 (-0.02%)
MSFT   317.00 (+1.15%)
META   302.04 (+0.37%)
GOOGL   133.92 (+1.13%)
AMZN   126.72 (+1.60%)
TSLA   252.46 (+2.41%)
NVDA   439.51 (+1.00%)
NIO   8.53 (-0.93%)
BABA   84.06 (-0.57%)
AMD   100.73 (+0.65%)
T   14.60 (-1.22%)
F   12.03 (-0.33%)
MU   67.82 (-0.01%)
CGC   0.68 (-1.19%)
GE   108.26 (+0.46%)
DIS   79.50 (-0.05%)
AMC   7.96 (+1.40%)
PFE   33.89 (-0.03%)
PYPL   58.03 (+1.27%)
NFLX   378.86 (+0.56%)
S&P 500   4,240.70 (+0.27%)
DOW   33,005.82 (+0.01%)
QQQ   357.48 (+0.72%)
AAPL   172.36 (-0.02%)
MSFT   317.00 (+1.15%)
META   302.04 (+0.37%)
GOOGL   133.92 (+1.13%)
AMZN   126.72 (+1.60%)
TSLA   252.46 (+2.41%)
NVDA   439.51 (+1.00%)
NIO   8.53 (-0.93%)
BABA   84.06 (-0.57%)
AMD   100.73 (+0.65%)
T   14.60 (-1.22%)
F   12.03 (-0.33%)
MU   67.82 (-0.01%)
CGC   0.68 (-1.19%)
GE   108.26 (+0.46%)
DIS   79.50 (-0.05%)
AMC   7.96 (+1.40%)
PFE   33.89 (-0.03%)
PYPL   58.03 (+1.27%)
NFLX   378.86 (+0.56%)
S&P 500   4,240.70 (+0.27%)
DOW   33,005.82 (+0.01%)
QQQ   357.48 (+0.72%)
AAPL   172.36 (-0.02%)
MSFT   317.00 (+1.15%)
META   302.04 (+0.37%)
GOOGL   133.92 (+1.13%)
AMZN   126.72 (+1.60%)
TSLA   252.46 (+2.41%)
NVDA   439.51 (+1.00%)
NIO   8.53 (-0.93%)
BABA   84.06 (-0.57%)
AMD   100.73 (+0.65%)
T   14.60 (-1.22%)
F   12.03 (-0.33%)
MU   67.82 (-0.01%)
CGC   0.68 (-1.19%)
GE   108.26 (+0.46%)
DIS   79.50 (-0.05%)
AMC   7.96 (+1.40%)
PFE   33.89 (-0.03%)
PYPL   58.03 (+1.27%)
NFLX   378.86 (+0.56%)
NYSEARCA:XPH

SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News

$38.62
+0.02 (+0.05%)
(As of 09:37 AM ET)
Compare
Today's Range
$38.56
▼
$38.62
50-Day Range
$38.61
▼
$44.12
52-Week Range
$38.41
▼
$44.31
Volume
521 shs
Average Volume
47,132 shs
Market Capitalization
$202.76 million
Assets Under Management
$187.29 million
Dividend Yield
1.73%
Net Expense Ratio
0.35%
ProfileChartHeadlinesHoldingsOptions ChainRatings

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

XPH Price History

XPH ETF News Headlines

September 18, 2023 | msn.com
SPDR Portfolio Mid Cap ETF declares quarterly distribution of $0.1758
June 25, 2023 | msn.com
What is behind big pharma's underperformance?
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
June 21, 2023 | msn.com
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1235
May 31, 2023 | markets.businessinsider.com
SPY ETF Gains 11% YTD: Technical Indicators Signal Further Upside
April 12, 2023 | marketwatch.com
When Spdr S&p Pharmaceuticals ($XPH) Moves Investors should Listen
March 22, 2023 | seekingalpha.com
XPH SPDR S&P Pharmaceuticals ETF
January 3, 2023 | seekingalpha.com
SPYV: How Microsoft And Amazon Changed The S&P 500 Value Index
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
December 27, 2022 | seekingalpha.com
Eli Lilly: Right Industry, Wrong Price
See More Headlines
Receive XPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Pharmaceuticals ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:XPH
Inception Date
6/19/2006
Fund Manager
Michael Feehily, Karl Schneider, Keith Richardson
Web
www.spdrs.com
Phone
+1-617-6644738

Fund Focus

Asset Class
Equity
Benchmark
S&P Pharmaceuticals Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
40

Fund Statistics

Assets Under Management
$192.06 million
Average Daily Volume
$39,320.00
Discount/Premium
0.01%

Administrator, Advisor and Custodian

Administrator
SSgA Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Options

Optionable
Optionable
Options Volume
10
Put Options
10
Call Options
1
Short Interest
460,900 shs

Miscellaneous

Outstanding Shares
5,250,000
Beta
0.84
Creation Unit
50,000
Creation Fee
$250.00
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

SPDR S&P Pharmaceuticals ETF Expenses

TypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.57%0.53%0.50%0.50%
Other Expenses0.00%0.40%0.52%0.64%0.57%
Total Expense0.35%0.72%0.69%0.74%0.69%
Fee Waiver0.00%-0.51%-0.55%-0.69%-0.58%
Net Expense0.35%0.61%0.59%0.57%0.57%

SPDR S&P Pharmaceuticals ETF (XPH) Holdings & Exposure

Top 10 XPH Holdings

XPH Sector Exposure

XPH Industry Exposure

Full Holdings Details

Key Executives

  • James E. Ross (Age 52)
    President, Trustee
  • Peter A. Ambrosini (Age 69)
    Chief Compliance Officer
  • Michael P. Riley (Age 44)
    Vice President
  • Gary L. French (Age 64)
    Treasurer
  • John W. Clark (Age 46)
    Assistant Treasurer
  • Matthew W. Flaherty (Age 42)
    Assistant Treasurer
  • Chad C. Hallett (Age 47)
    Assistant Treasurer of Street tracks series trust
  • Mary Moran Zeven (Age 52)
    Secretary
  • Scott M. Zoltowski (Age 44)
    Assistant Secretary
  • Dave Kelly
    Independent Trustee

Similar ETFs

Institutional Ownership

View All Institutional Transactions













XPH ETF - Frequently Asked Questions

How have XPH shares performed in 2023?

SPDR S&P Pharmaceuticals ETF's stock was trading at $40.95 at the beginning of 2023. Since then, XPH stock has decreased by 5.7% and is now trading at $38.61.
View the best growth stocks for 2023 here.

What does XPH invest in?

SPDR S&P Pharmaceuticals ETF is a equity fund issued by SSgA. XPH focuses on health care investments and follows the S&P Pharmaceuticals Index. The fund's investments total to approximately $192.06 million assets under management.

What stocks does SPDR S&P Pharmaceuticals ETF hold?

XPH invests in 40 holdings. Some of the stocks in their portfolio include Reata Pharmaceuticals (RETA), Elanco Animal Health (ELAN), Catalent (CTLT), Zoetis (ZTS), Viatris (VTRS), Axsome Therapeutics (AXSM), Johnson & Johnson (JNJ), Jazz Pharmaceuticals (JAZZ), Eli Lilly and Company (LLY) and Organon & Co. (OGN).

What is the management fee for SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XPH is 0.35%.

What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Pharmaceuticals ETF investors own include Pfizer (PFE), Bank of America (BAC), Micron Technology (MU), Broadcom (AVGO), Chevron (CVX), DocuSign (DOCU), SPDR Gold Shares (GLD), International Business Machines (IBM), JPMorgan Chase & Co. (JPM) and AT&T (T).

What is SPDR S&P Pharmaceuticals ETF's stock symbol?

SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XPH."

How do I buy shares of SPDR S&P Pharmaceuticals ETF?

Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SPDR S&P Pharmaceuticals ETF's stock price today?

One share of XPH stock can currently be purchased for approximately $38.61.

How much money does SPDR S&P Pharmaceuticals ETF make?

SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) has a market capitalization of $202.70 million.

How can I contact SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF's mailing address is State Street Financial Center One Lincoln Street, BOSTON, MA 02111, United States. The official website for the company is www.spdrs.com. The company can be reached via phone at +1-617-6644738.

This page (NYSEARCA:XPH) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -